Search filters

List of works by Ryohei Katayama

3D culture system containing gellan gum restores oncogene dependence in ROS1 rearrangements non-small cell lung cancer.

scientific article published on 9 May 2018

A safety study of newly generated anti-podoplanin-neutralizing antibody in cynomolgus monkey (Macaca fascicularis)

scientific article published on 07 September 2018

AP-1-Dependent miR-21 Expression Contributes to Chemoresistance in Cancer Stem Cell-Like SP Cells ⬇️

scientific article published on January 1, 2010

APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.

scientific article published on 8 February 2017

Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1

scientific article

Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function

scientific article

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.

scientific article published on 13 March 2017

Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer

scientific article

Casein kinase 2-interacting protein-1, a novel Akt pleckstrin homology domain-interacting protein, down-regulates PI3K/Akt signaling and suppresses tumor growth in vivo.

scientific article

Cell differentiation inducers derived from thalidomide.

scientific article published on July 2005

Cell-permeable Carboxyl-terminal p27Kip1 Peptide Exhibits Anti-tumor Activity by Inhibiting Pim-1 Kinase

scientific article

Cellular FLIP inhibits beta-catenin ubiquitylation and enhances Wnt signaling.

scientific article published on October 2004

Complex N-glycosylated form of nicastrin is stabilized and selectively bound to presenilin fragments.

scientific article

Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.

scientific article published on 18 April 2013

Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export.

scientific article

Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer

scientific article published on 16 January 2018

Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms

scientific article published on 08 February 2020

Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status

scientific article published on 08 February 2019

GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer

scientific article published on 17 March 2022

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer

scientific article published on 24 February 2021

Identification of mutation accumulation as resistance mechanism emerging in first-line osimertinib treatment.

scientific article published on 24 April 2018

Impairment of the ubiquitin-proteasome system by cellular FLIP.

scientific article

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers ⬇️

scientific article published on January 25, 2012

Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers

scientific article published on 27 July 2017

Modulation of Wnt signaling by the nuclear localization of cellular FLIP-L.

scientific article

Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR

scientific article published on 02 May 2021

Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer

scientific article published on 13 January 2020

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer

scientific article published on 12 December 2015

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

scientific article published on 2 July 2015

Patient-derived models of acquired resistance can identify effective drug combinations for cancer.

scientific article

Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels

scientific article

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance

scientific article published on 17 January 2019

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

scientific article

Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response

scientific article published on 23 May 2018

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

scientific article

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer

scientific article published on 14 March 2019

TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity.

scientific article

TUSC4/NPRL2, a novel PDK1-interacting protein, inhibits PDK1 tyrosine phosphorylation and its downstream signaling

scientific article

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

scientific article

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models

scientific article published on 09 August 2019

Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer.

scientific article published on 6 February 2017

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.

scientific article

Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.

scientific article published on May 2015

Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance

scientific article published on 13 October 2014

Transforming growth factor-β decreases the cancer-initiating cell population within diffuse-type gastric carcinoma cells.

scientific article published on 6 December 2010

Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib

scientific article

US phase 1 first-in-human study of taletrectinib (DS-6051b/AB-106), a ROS1/TRK inhibitor, in patients with advanced solid tumors

scientific article published on 26 June 2020

Paulina is supported by:

About Paulina

Help